NeuroPace jumps as Medicare boosts pay for epilepsy device procedures

Shares of medical device maker Neuropace NPCE.O rise 2.1% to $14.65 premarket

Co says Medicare will increase payments for its RNS System, a device used to treat drug-resistant epilepsy

Under new rules for 2026, the Centers for Medicare & Medicaid Services or CMS, will raise payments to doctors who implant or replace the RNS System by about 43% for initial procedures and 45% for replacements - NPCE

CMS also moves RNS replacement to highest-paying outpatient category, lifting hospital reimbursement by 47% to $31,526 - NPCE

Co expects the higher payments to support growth in both physician use and hospital access for Medicare patients

Up to last close, stock up ~28% YTD